Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 3,010 | 待询 | ||
10 mg | ¥ 5,560 | 待询 | ||
50 mg | ¥ 17,035 | 待询 | ||
100 mg | ¥ 29,785 | 待询 | ||
200 mg | 待询 | 待询 | ||
500 mg | 待询 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 4,005 | 待询 |
FGTI-2734 mesylate (1247018-19-4 free base) 的其他形式现货产品:
产品描述 | FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors. |
靶点活性 | GGT:520 nM , FT:250 nM |
体外活性 | FGTI-2734 mesylate (3-30 μM;?72 hours) inhibits both protein prenylation of HDJ2, RAP1A, KRAS and NRAS. FGTI-2734 mesylate (1-30 μM; 72 hours) induces apoptosis in mutant KRAS-dependent, but not mutant KRAS- independent, human cancer cells. ??FGTI-2734 inhibits KRAS membrane localization in RAS-transformed murine NIH3T3 cells and in mutant KRAS human cancer cells. |
体内活性 | FGTI-2734 mesylate (intraperitoneally;?100 mg/kg/day for 18 to 25 days) only inhibits tumor growth in mutant KRAS-dependent tumors but not in mutant KRAS-independent tumors. |
别名 | FGTI-2734 mesylate |
分子量 | 606.73 |
分子式 | C27H35FN6O5S2 |
CAS No. | 2702297-24-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 75 mg/mL (123.61 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.6482 mL | 8.2409 mL | 16.4818 mL | 41.2045 mL |
5 mM | 0.3296 mL | 1.6482 mL | 3.2964 mL | 8.2409 mL | |
10 mM | 0.1648 mL | 0.8241 mL | 1.6482 mL | 4.1204 mL | |
20 mM | 0.0824 mL | 0.412 mL | 0.8241 mL | 2.0602 mL | |
50 mM | 0.033 mL | 0.1648 mL | 0.3296 mL | 0.8241 mL | |
100 mM | 0.0165 mL | 0.0824 mL | 0.1648 mL | 0.412 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
FGTI-2734 mesylate (1247018-19-4 free base) 2702297-24-1 Others FGTI-2734 Mesylate FGTI2734 Mesylate FGTI-2734 mesylate FGTI2734 mesylate (1247018194 free base) 1247018-19-4 1247018-19-4 free base FGTI 2734 mesylate (1247018 19 4 free base) FGTI 2734 Mesylate Inhibitor inhibitor inhibit